The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients.

Cancer patients in developing and low-income countries have limited access to target therapies. For example, tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukaemia patients (CML) is often delayed. In Bosnia, 16% of patients received immediate TKI treatment (<3 months of diagnosis), while 66% of patients received therapy after a median 14-month wait period.

[Diagnostic value and cytomorphologic findings in bone marrow punctures in children with severe deficiency anemia].

Aims: To determine the diagnostic and prognostic value the bone marrow aspiration in children with severe deficiency anaemia.

Patients And Methods: In this retrospective study we analysed 75 children 0-4 years of age who were diagnosed and treated from severe anaemia (Hb < 8g/dl) at Haematologic outpatient and hospital department of Pediatric Clinic in Sarajevo in period of 01.01.

[Treatment of myeloproliferative diseases].

The modern treatment of the myeloproliferative disease is based on knowledge about pathogenic tumour's growing up and basically the treatment is based on the use of cytoxic therapy. The mix of cytotoxic is bringing up to the reducing of disease at the some percentages. Related the above disease in practice interferons showed themselves quite efficiently and in practice of allogenic transplantation of marrow bone is gave and a possibility of recovery of the chronic myeloid leukemia.